Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmJC histone demethylases

Bhaskar Bhushan a,b,e, Alexandre Erdmann a,e, Yijia Zhang a, Roman Belle a, Catrine Johansson a,c, Udo Oppermann c, Richard J. Hopkinson a,d, Christopher J. Schofield a, Akane Kawamura a,b,e

⇑
a Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom
b Radcliffe Department of Medicine, Division of Cardiovascular Medicine, University of Oxford, The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, United Kingdom
c Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, United Kingdom

A R T I C L E   I N F O

Article history:
Received 15 February 2018
Revised 10 March 2018
Accepted 18 March 2018
Available online 19 March 2018

Keywords:
Epigenetics
PHD-finger inhibitor
Plant Homeodomain
JmJC-KDMs
Histone demethylases

Abstract

Plant homeodomain (PHD) finger containing proteins are important epigenetic regulators and are of interest as potential drug targets. Inspired by the amiodarone derivatives reported to inhibit the PHD finger 3 of KDM5A (KDM5A(PHD3)), a set of compounds were synthesised. Amiodarone and its derivatives were observed to weakly disrupt the interactions of a histone H3K4me3 peptide with KDM5A(PHD3). Selected amiodarone derivatives inhibited catalysis of KDM5A, but in a PHD-finger independent manner. Amiodarone derivatives also bind to H3K4me3-binding PHD-fingers from the KDM7 subfamily. Further work is required to develop potent and selective PHD finger inhibitors.

© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Contents

1. Introduction ........................................................................................................ 2984
2. Results. ............................................................................................................. 2985
   2.1. Synthesis of AMI derivatives ........................................................................ 2985
   2.2. Development of KDM5A(PHD3) AlphaScreen binding assay ...................... 2988
   2.3. Inhibition of KDM5A demethylation activity by AMI derivatives ............... 2988
   2.4. Inhibition of H3K4me3-binding PHD-fingers of other JmJC-KDMs by AMI derivatives ............................... 2989
   2.5. Inhibition of binding and catalytic activity of KDM7A/B(PHD-JmJC) by AMI derivatives ............................... 2989
3. Discussion. ........................................................................................................ 2990
   Acknowledgments ............................................................................................. 2990
   Funding. .......................................................................................................... 2990
A. Supplementary data. .......................................................................................... 2990
References .......................................................................................................... 2990

1. Introduction

Most human genes are subject to epigenetic regulation, including by the post-translational modifications of histones. These ‘epigenetic marks’ are recognised and maintained by a diverse set of regulatory proteins and enzymes.1 The maintenance of these marks is vital for the functioning and maintenance of cells, and their dysregulation is linked to multiple diseases, including cancer, cardiovascular disease, and developmental disorders.2–5

Plant homeodomain (PHD) fingers are C4HC3 type zinc-finger binding domains present in many chromatin-modifying proteins.6,7 These small 50–100 residue domains bind to histones to enable the localisation of enzyme(s) to specific targets and...
promote the recruitment of transcription factors or chromatin-associated protein complexes. While the roles of many PHD-fingers are unclear, some PHD-fingers recognise specific histone modifications, including non-methylated or methylated lysines (e.g., histone H3 at K4 and K9), arginines (e.g., H3R2me1/me2), and acetylated lysines (e.g., H3K14). PHD-fingers can also function as allosteric modulators of the activities of associated enzymes. Mutations, deletions or chromosomal translocations of PHD-finger encoding genes are linked to a range of diseases, including cancer, immunodeficiency and neurological disorders; thus PHD-fingers are important epigenetic regulators.

Histone modifying enzymes, such as in the Jumonji-C (JmjC) domain-containing histone lysine demethylases (JmjC-KDMs), sometimes contain multiple PHD-fingers (Fig. 1). The KDM5 subfamily of JmjC-KDMs (KDM5A-D) catalyses demethylation of the transcriptionally activating tri- and di-methylated lysine-4 mark on histone H3 (H3K4me3/2), and is generally associated with transcriptional repression. The KDM5s are associated with development and progression of multiple cancers, and can mediate cancer cell drug tolerance and maintain tumour-initiating cells. KDM5A/B have three PHD-fingers (PHD1-3, numbered sequentially from the N-terminus), whereas KDM5C/D have two. The roles of KDM5 PHD-fingers are partially characterised: KDM5A/B(PHD3) binds to H3K4me3, with decreasing affinity for lower methylation states; whereas KDM5A/B(PHD1) recognizes H3K4me0 (demethylation product), and is implicated in ‘allosteric’ activation of KDM5 catalysis. It is proposed that PHD3 of KDM5A/B directs the JmjC domain to the H3K4me3 site; PHD1 binds to the demethylated product H3K4me0 and activates the JmjC domain through a positive-feedback mechanism. This is thought to propagate the transcriptionally inactive state of chromatin by K4me3 removal along the H3K4me3-enriched promoters. KDM5A(PHD3) is implicated in acute myeloid leukemia (AML) and forms a fusion protein with nucleoprotein 98 (NUP98), a common translocation partner. This fused KDM5A(PHD3):NUP98 found in AML patients directs the “oncoprotein” to H3K4me3 promoter sites, inducing aberrant active transcription leading to AML, as shown in cellular and animal models. PHD3 mutations that disrupt H3K4me3 binding inhibit leukemic transformation. In ER+ breast cancers, KDM5A promotes progression and metastasis, but its critical role in metastasis is apparently independent of its catalytic activity and regulated by the N-terminal PHD1/ARID domain regions. A point mutation (A388P) in KDM5C(PHD1) is linked to patients with X-linked mental retardation, and manifests reduced H3K4 demethylase activity. Overall, these results identify their PHD-finger domains to be crucial to the KDM5 function(s) (both catalytic and non-catalytic), and in addition to JmjC-targeting, suggest they are interesting targets for oncology.

By contrast to the catalytic domains of epigenetic proteins, (e.g., DNA methyltransferases, histone deacetylases, histone methyltransferases, demethylases and bromodomains), chemical tools for PHD-fingers are lacking and progress towards inhibitor development has been limited. PHD-finger inhibitors will be useful in exploring their biological functions and therapeutic potential.

In 2012, Wagner et al. identified amiodarone (AMI), an antiarrhythmic drug, as an inhibitor of KDM5A(PHD3). Analogues of AMI (WAG-003, WAG-005) were reported to inhibit the binding of KDM5A(PHD3) to H3K4me3 with $IC_{50}$ values of 30 ± 14 µM and 41 ± 16 µM, respectively, on the basis of a HaloTag-based peptide displacement assay, and supported by fluorescence polarisation assay results. While WAG-003 also inhibited other H3K4me3 binding domains (PHD in RAG and double tudor domain (DTD) in KDM4A), it showed modest selectivity over other tested PHD-fingers and Tudor domains (AIRE PHD1, BHC80 PHD, UHRF1 (TDD)). However, the mode of action of AMI derivatives and their potential effect on KDM5A catalytic activity was unclear.

We describe the synthesis of a series of AMI derivatives and structure-activity-relationship (SAR) studies on their KDM5A (PHD3) binding and H3K4me3 demethylation catalysis by KDM5A (Fig. 2). The results reveal that, while AMI and its derivatives bind weakly to PHD-fingers of KDM5A and other PHD-fingers within the JmjC-KDMs, they also inhibit the demethylation activity in a PHD-finger independent manner, suggesting AMI derivatives can act via more than one binding mode.

2. Results

2.1. Synthesis of AMI derivatives

The AMI derivatives were synthesised as in Scheme 1. To explore the importance of alkylation at the 2-position of the benzofuran core, benzo[4]furan derivatives 3 were reacted with 4-methoxybenzoyl chloride 4 using AlCl$_3$ mediated Friedel-Crafts acylation to give 5a-d. AlCl$_3$-mediated demethylation yielded 6a-d; alkylation of the phenol of these with N,N-dimethyl-3-chloropropylamine afforded dimethylated lysine analogues 1a-d.
Treatment with iodomethane gave the corresponding quaternary ammonium compounds 2a–d. For diversification at the aryl portion of AMI, 3a and 3b (Scheme 1b) were employed. 3,4,5-Trimethoxybenzoyl chloride and 3,5-difluoro-4-methoxybenzoyl chloride were used to prepare 8a and 8b respectively. 2-Methoxybenzoyl chloride was used to prepare 7a and 7b, the regioisomers of 2a and 2b, respectively, to investigate the effect of altering the position of the 3-(trimethylammino)-propoxy group from the para- to the ortho-position.

To explore the importance of the quaternary ammonium of histone lysines for binding to KDM5A(PHD3), different alkylated amines of AMI were prepared, starting from 6a (Scheme 2). Thus, alkylation of 6a gave 9, which was deprotected to give primary amine 10. Mitsunobu reaction of 6a with NN-diethyl-3-amino-propanol gave 11 in moderate yield, which was converted to 12 by reaction with iodoethane.34

2.2. Development of KDM5A(PHD3) AlphaScreen binding assay

To assess whether the AMI derivatives inhibit binding of histone H3K4me3 peptide to KDM5A(PHD3), we developed an AlphaScreen displacement assay. AlphaScreen is a homogenous bead-based assay used to study protein-protein interactions.28 We used a streptavidin-conjugated donor and nickel-conjugated acceptor bead pair to detect the interactions of His6-tagged KDM5A(PHD3) (His-KDM5A(PHD3)) and C-terminally biotinylated-H3(1–21)K4me3 (H3K4me3-Bn) (Fig. 3A). Optimised assay conditions were determined to ensure that the His-KDM5A(PHD3) and H3K4me3-Bn interactions could be detected in the linear range of the assay, with good signal-to-background ratio (Supplementary Fig. S1). To investigate the inhibition of the protein-peptide interaction, His-KDM5A(PHD3) was pre-incubated with compounds (15 min), followed by incubation with H3K4me3-biotin (30 min). AlphaScreen beads were then added and incubated for 1 h. Changes in
the AlphaScreen signals with increasing inhibitor concentrations were then measured to quantify the level of KDM5A(PHD3) and H3K4me3 binding, and IC50 values were determined. Using this setup, IC50 values for displacement of biotinylated H3K4me3 by non-biotinylated histone peptides were seen to decrease with increasing methylation state at H3K4 (Kme3 < Kme2 < Kme1 < Kme0) (Supplementary Fig. S2) confirming the rank order of peptide affinities to KDM5A(PHD3), as previously reported based on isothermal titration calorimetry.20 Following assay optimisation, the set of AMI derivatives was tested for KDM5A (PHD3) inhibitory activity (Table 1, Fig. 3B, Supplementary Fig. S3).

Interestingly, although the AlphaScreen-based peptide displacement assay works on similar principles to the HaloTag assay reported by Wagner et al.,26 IC50 values measured against KDM5A(PHD3) differed for the set of AMI derivatives in our assays. Whilst WAG-005 and WAG-003 are reported to have IC50 values of 30–40 \( \mu \)M using the Halo-tag assay, they had >10-fold (562 \( \mu \)M) and >50-fold higher IC50 values (1658 \( \mu \)M), respectively, in our assay. While AMI had an IC50 value of 99 \( \mu \)M, non-specific interference of AMI (and some derivatives) with the AlphaScreen assay in the counter screen using biotin-His6 was observed (Table 1). Taking this into account, SAR analysis of further AMI variants on KDM5A(PHD3) indicates that removal of the 3,5-di-ido substitutions from the WAG-005 aryl group increased potency (2a, IC50 = 340 \( \mu \)M); alternative substitutions (3,5-dimethoxy (8a), 3,5-difluoro (8b)) were also favourable (198 \( \mu \)M, 223 \( \mu \)M respectively). The results reveal that \( p \)-substitution (2a) is favoured over \( o \)-substitution (7a) for the 3-(trimethylammino)-propoxy group.

**Fig. 3.** Screening of AMI analogues for binding and catalytic inhibition of KDM5A. (A) AlphaScreen assay for H3K4me3 and His-KDM5A(PHD3) interactions. (B) Normalised dose–response inhibition curves for displacement of H3K4me3-Bn from KDM5A(PHD3) by representative AMI derivatives. Average ± StdDev (N ≥ 3 independent replicates). (C, D) Dose-response inhibition curves of H3K4me3 demethylation activity by AMI derivatives for KDM5A using a MALDI-TOF MS-based assay. AMI derivatives were tested against two active KDM5A constructs, KDM5A_c1 (M1-L801), and KDM5A_c2 (ARID1/PHD1, L88-G353). KDOAM25a is a small molecule JmjC-domain inhibitor of KDM5.

**Scheme 2.** Modification of the quaternary ammonium group of potential PHD inhibitors.
Alkylation of amines was then explored (2a, 7a, 10, 12). The tertiary amine (di-methyl (1a)) was the most potent inhibitor with an IC50 value of 166 μM, followed by the primary amine (10), with the quaternary amine (tri-methyl- (2a), tri-ethyl (12)) being least potent. Reducing the length of the alkyl chain at R1 from butyl (2a) to methyl led to a reduction in activity (2b). The benzophenone (2c) was more potent than 2b for KDM5A(PHD3), whilst the N-methylindole analogue (2d) had reduced activity. These studies suggest that further exploration and diversification of the heterocyclic rings is of interest. Overall, the most potent inhibitor in this panel against KDM5A(PHD3) was 1a with an IC50 of 166 μM.

### 2.3. Inhibition of KDM5A demethylation activity by AMI derivatives

We next investigated the effect of AMI derivatives on the demethylation activity of KDM5A. Two catalytically active constructs of KDM5A were employed, KDM5A_c1 (M1-L801) and KDM5A_c2 (DARID/PHD1, P13-S744 with L88-G353 (ARID/PHD1) replaced with a GGGG linker) and both KDM5A_c1 and KDM5A_c2 constructs lack the PHD2 and PHD3. We thus proposed that KDM5A catalytic activity should not be affected by AMI derivatives since the PHD3 domain in these proteins is absent. A MALDI-TOF MS assay was used to measure the activity of H3K4me3 demethylation in the presence of inhibitors (Table 2, Fig. 3C and D).

KDOAM25, a KDM5-selective JmjC-domain targeting small molecule inhibitor,29 was used as a positive control. Interestingly, while AMI was not an inhibitor of KDM5A activity, WAG-005 and 2a inhibited demethylation activity of both KDM5A_c1 and KDM5A_c2, at concentrations significantly below the AlphaScreen displacement IC50 values with isolated PHD3 (Table 2, Supplementary Fig. S6).

This suggests that both WAG-005 and 2a can inhibit the catalytic activity of KDM5A in a manner independent of PHD-finger binding, presumably via binding to the JmjC domain. Further kinetic analysis of KDM5A_c2 using formaldehyde dehydrogenase (FDH) enzyme-coupled fluorescence assay indicated that 2a replaced with a GGGG linker) and both KDM5A_c1 and KDM5A_c2 constructs lack the PHD2 and PHD3. We thus proposed that KDM5A catalytic activity should not be affected by AMI derivatives since the PHD3 domain in these proteins is absent. A MALDI-TOF MS assay was used to measure the activity of H3K4me3 demethylation in the presence of inhibitors (Table 2, Fig. 3C and D).

KDOAM25, a KDM5-selective JmjC-domain targeting small molecule inhibitor,29 was used as a positive control. Interestingly, while AMI was not an inhibitor of KDM5A activity, WAG-005 and 2a inhibited demethylation activity of both KDM5A_c1 and KDM5A_c2, at concentrations significantly below the AlphaScreen displacement IC50 values with isolated PHD3 (Table 2, Supplementary Fig. S6).

This suggests that both WAG-005 and 2a can inhibit the catalytic activity of KDM5A in a manner independent of PHD-finger binding, presumably via binding to the JmjC domain. Further kinetic analysis of KDM5A_c2 using formaldehyde dehydrogenase (FDH) enzyme-coupled fluorescence assay indicated that 2a

### Table 1

AMI derivatives (Fig. 2) and associated Alphascreen IC50 values for displacement of H3K4me3-Bn from His-KDM5A(PHD3). Average ± StdDev (n ≥ 3 independent replicates) shown. H3(1–21)K4me3 IC50: 218 ± 16 nM.

| Compounds | A | R1 | R2 | R3 = R5 | R4 | IC50 (μM) | Biotin-His6 counterscreen |
|-----------|---|----|----|---------|----|-----------|--------------------------|
| Amiodarone (AMI) | O | butyl | H | I | | 99 ± 23 | 178 ± 58 |
| WAG-003 | O | butyl | H | I | | 1658 ± 490 | 11280 ± 1258 |
| WAG-005 | O | butyl | H | I | | 562 ± 130 | 2584 ± 127 |
| 1a | O | butyl | H | H | | 166 ± 20 | 484 ± 82 |
| 2a | O | butyl | H | H | | 340 ± 44 | 4297 ± 163 |
| 2b | O | methyl | H | H | | 844 ± 23 | 6291 ± 1865 |
| 2c | S | methyl | H | H | | 533 ± 109 | 805 ± 55 |
| 2d | NMe | H | H | H | | 1310 ± 39 | 970 ± 60 |
| 7a | O | butyl | H | H | | 1146 ± 100 | DNC |
| 7b | O | methyl | H | H | | 2305 ± 82 | DNC |
| 8a | O | butyl | H | OMe | | 223 ± 60 | 309 ± 70 |
| 8b | O | butyl | H | F | | 198 ± 50 | 455 ± 57 |
| 9 | O | butyl | H | H | | 198 ± 41 | 376 ± 69 |
| 10 | O | butyl | H | H | | 314 ± 30 | 1335 ± 326 |

**Notes:**
- DNC: data did not converge to binding model.
- NM: not measurable within the solubility range of the compound. Final concentration of protein and peptide were 25 nM.
Table 2
Inhibition of H3K4me3 demethylation activity of KDM5A using MALDI-TOF MS assays. Dose-response inhibition assays were carried out with AMI derivatives or KDDAM25 using different constructs of KDM5A. Average ± StdDev of n = 2 independent assays.

| Compounds | IC₅₀ (µM) |
|-----------|-----------|
|           | KDM5A_c1  | KDM5A_c2  |
| AMI       | >1000     | >1000     |
| WAG-005   | 82 ± 54   | 27 ± 2    |
| 1a        | >1000     | >1000     |
| 2a        | 80 ± 29   | 37 ± 14   |
| KDDAM25   | 1.7 ± 0.6 | 3.2 ± 3.1 |

binding is unlikely to be competitive with respect to H3K4me3 binding \((\alpha = 1.64 ± 0.85, K_i = 74 ± 28 \mu M)\) (Supplementary Fig. S6A, B). No formaldehyde production was detected with 2a in the absence of H3K4me3, suggesting that 2a is not a substrate of KDM5A_c2, at least, under the assay conditions tested (Supplementary Fig. S6C).

2.4. Inhibition of H3K4me3-binding PHD-fingers of other JmjC-KDMs by AMI derivatives

In order to test the specificity of the AMI derivatives for KDM5A, cross-screens were performed using AlphaScreen binding assays against the H3K4me3-binding PHD-fingers associated with other JmjC-KDMs: KDM7A(KIAA1718), KDM7B(PHF8) and KDM7C (PHF2) (Fig. 1A, Supplementary Figs. S4, S5). The PHD-fingers of the KDM7 subfamily recognise H3K4me3.30,31 In the case of KDM7B, the PHD-finger primes the JmjC domain to catalyse demethylation of nearby H3K9me2 (Fig. 1). Conversely, in KDM7A, binding of H3K4me3 to the PHD-finger negatively affects the demethylation activity of the JmjC domain at the H3K9me2 site, likely due to the spacing constrains between the two domains.30

The majority of AMI derivatives weakly inhibited histone peptide binding by the KDM7 PHD-fingers, albeit to varying degrees (Table 3, Fig. 4). As observed with KDM5A(PHD3), there was little consensus in terms of the preferred methylation and substitution state of the amine group, with the trimethylammonium group containing WAG-005 being most effective against KDM7A(PHD), the triethylamino group containing compound 12 being most effective against KDM7B(PHD), and the dimethylamino group containing 1a being most effective against KDM7C(PHD). This was somewhat surprising, given the ~88% sequence similarity between the KDM7 PHD-fingers. Additionally, there was a preference for the 3-(trimethylamine)-propoxy group in WAG-005 over the 2-(trimethylamino)-ethoxy group in WAG-003 for binding to KDM7A(PHD).

As observed for KDM5A(PHD3), all AMI derivatives with o-substitutions (7a) were less potent than those with p-substitutions (2a); the 3,5-dimethoxy- and difluoro-containing compounds 8a and 8b were more potent than their unsubstituted analogue 2a. There was less agreement in the effect of the removal of the 3,5-diiodo-groups, which reduced potency against KDM7A(PHD), and improved potency against KDM7B(PHD) and KDM7C(PHD) (Table 3, Fig. 4). Divergent trends are also observed in the heterocyclic region (2b, 2c, and 2d); N-methylindole 2d was most potent against KDM7A(PHD), benzofuran 2b was most potent against KDM7B(PHD), and the benzothiophene-containing 2c was most potent against KDM7C(PHD). Overall, the results reveal that AMI derivatives inhibit the KDM7 PHD-fingers, indicating that they are likely not selective. WAG-003 and WAG-005 inhibited the PHD-fingers of KDM7s at different potencies, with WAG-005 being the most potent inhibitor of KDM7A(PHD).

Table 3
AlphaScreen IC₅₀ Values for displacement of H3K4me3-Bn from His-KDM7(PHD) by AMI derivatives. Final concentrations of protein and H3K4me3-Bn were: 6.25 nM KDM7A(PHD) and 25 nM peptide, 12.5 nM each for KDM7B(PHD), and 25 nM KDM7C (PHD) and 6.25 nM peptide. Average ± StdDev (n ≥ 3 independent replicates) shown.

| Compounds | IC₅₀ (µM) |
|-----------|-----------|
|           | KDM7A(PHD) | KDM7B(PHD) | KDM7C(PHD) |
| AMI       | 156 ± 12   | 252 ± 53   | 84 ± 14    |
| WAG-003   | 2232 ± 790 | 307 ± 76   | 976 ± 146  |
| WAG-005   | 50 ± 5     | 390 ± 158  | 740 ± 149  |
| 1a        | 333 ± 39   | 397 ± 77   | 158 ± 30   |
| 2a        | 86 ± 9     | 355 ± 39   | 579 ± 87   |
| 2b        | 108 ± 15   | 310 ± 78   | 598 ± 119  |
| 2c        | 104 ± 8    | 377 ± 76   | 501 ± 75   |
| 2d        | 98 ± 10    | 697 ± 154  | 682 ± 97   |
| 7a        | 102 ± 15   | 496 ± 181  | 1294 ± 280 |
| 7b        | 326 ± 14   | 286 ± 84   | 533 ± 99   |
| 8a        | 76 ± 14    | 240 ± 58   | 228 ± 66   |
| 8b        | 68 ± 13    | 242 ± 41   | 220 ± 40   |
| 10        | 534 ± 150  | 386 ± 41   | 359 ± 89   |
| 12        | 151 ± 17   | 221 ± 57   | 334 ± 45   |

H3[1–21]K4me3 1.9 ± 0.1 µM 1.7 ± 0.2 µM 2.7 ± 0.2 µM

Fig. 4. AlphaScreen binding assay for H3K4me3 and His-KDM7(PHD). Normalised dose–response inhibition curves for the displacement of H3K4me3-Bn from KDM7A/B/C by representative AMI derivatives.

2.5. Inhibition of binding and catalytic activity of KDM7A/B(PHD-JmjC) by AMI derivatives

We next explored the effect of AMI and select derivatives against the KDM7A/B JmjC domains. A dual-domain construct of KDM7A/B(PHD-JmjC), consisting of a JmjC domain in addition to the PHD-finger (Fig. 1B), was used to test for allosteric inhibition through binding at the PHD-finger. The displacement IC₅₀ profiles for the dual domains were significantly different, and generally lower, compared to that of the PHD finger-only constructs (Table 4). KDM7A(PHD-JmjC) was particularly sensitive, with IC₅₀ values of WAG-005 and 2b at 16 µM and 5.6 µM, respectively.

The AMI derivatives were then tested for inhibition of KDM7A/B-catalysed H3K9me2 demethylation using the MALDI-TOF MS assay. H3[1–15]K9me2 and H3[1–5]K4me3K9me2 were used as
substrates for KDM7A(PHD-jmjc) and KDM7B(PHD-jmjc), respectively. For KDM7A(PHD-jmjc), complete inhibition of K9me2 demethylation activity was observed for all AMI derivatives tested (except WAG-003) at 100 μM. For KDM7B(PHD-jmjc), inhibition was most pronounced for 1a (95%) and 2a (89%) whilst others inhibited more weakly (Table 4).

3. Discussion

AMI and its derivatives (WAG-003, WAG-005) have been identified as KDM5A(PHD3) inhibitors; they remain the only reported inhibitors of PHD-fingers linked to JmjC-KDMs. To investigate the tractability and selectivity of PHD-finger inhibition by this scaffold, we generated a series of AMI derivatives and assessed their SAR against KDM5A(PHD3) using an AlphaScreen-based binding assay. While some of the AMI derivatives did indeed weakly displace the H3K4me3 binding to KDM5A(PHD3), our results suggest their potencies are an order of a magnitude lower than previously reported. Small improvements in potency were obtained by modifying the 3,5-substitutions on the aryl group. We hypothesised that the tertiary amine in WAG-005 may be binding at the Nε-methylated lysine binding pocket of KDM5A(PHD3). However, no clear differences in binding potency were observed for derivatives with differing amine alkylation states, in agreement with previous findings. This is in contrast to histone H3 peptides, where higher differences in binding potency were observed for derivatives with differing lysine binding pocket of KDM5A(PHD3). However, no clear trend in their binding was observed for derivatives with differing lysine alkylation states, in agreement with previous findings. This is in contrast to histone H3 peptides, where higher differences in binding potency were observed for derivatives with differing lysine alkylation states, in agreement with previous findings.

Interestingly, some AMI derivatives inhibited the catalytic activity of the KDM5A and KDM7A/B jmjc domain, further indicating that they may act/bind via more than one mode. Kinetic analysis on 2a suggests that the binding is not competitive with respect to histone H3K4me3 (Supplementary Fig. S6). However, further biophysical analyses are needed to elucidate the precise modes of action of the compounds.

The AMI derivatives were also found to be promiscuous binders of the KDM7 PHD-fingers, and there was no clear trend in their binding profiles across the PHD-fingers. It is important to note that IC50 values are dependent on assay conditions. The differences between the assay setup, such as the length of peptide and protein constructs, can affect the absolute IC50 values (H3[1–21]K4me3 and KDM5A1542–1660 (PHD3) were used in our study compared to H3[1–11] or 1–14]K4me3 and KDM5A601–1660 (PHD3) used by Wagner et al.). It is possible that the increased binding affinity of the longer peptide ligand to the longer reader domain scaffold in our study may contribute to the higher IC50 values obtained. Indeed, it was well reported that the binding and catalytic activities change with different protein construct length and domain architecture, as demonstrated for the KDM5A and the KDM7 subfamilies in this study. Thus, while isolated protein domains and peptide fragments provide useful information, more work with full-length proteins and nucleosomes are likely needed for robust evaluation of small-molecule interactions.

The results presented here imply that AMI derivatives need further optimisation to be useful as probes for the PHD-fingers. More generally, they highlight the need for good quality PHD-finger inhibitors. Despite the emerging importance of the PHD-fingers in driving epigenetic changes in diseases and compelling biology to support PHD-finger as attractive cancer targets, the PHD-fingers have been considered difficult targets for small molecule inhibition. Our results support this view, highlighting the challenges in developing selective and potent small molecule inhibitors against the PHD-fingers.

Acknowledgments

We thank the Structural Genomics Consortium for the constructs for KDM5A, and Oliver Coleman for the assistance with MALDI-TOF MS assays and protein production.

Funding

This work was supported by the European Research Council Starting Grant [679479], Cancer Research UK Programme Grant [CB717/A182, AK, CJ] and project grant to UO, the Wellcome Trust [20341/2/16/12], British Heart Foundation Centre for Research Excellence Oxford [RE/13/1/30181], Arthritis Research UK [program grant 20522], Leducq Foundation, Rosetrees Trust, the Engineering and Physical Science Research Council, Foundation ARC (Fellowship to AE), and the Royal Society Dorothy Hodgkin Fellowship [DH120028 to AK]. RJH acknowledges a William R. Miller Junior Research Fellowship, St. Edmund Hall, Oxford.

A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.bmc.2018.03.030.

References

1. Willbanks A et al. The evolution of epigenetics: from prokaryotes to humans and its biological consequences. Genet Epigenet. 2016;8:25–36. https://doi.org/10.4137/Gep.31383.
2. Song YC, Wu FR, Wu JY. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol. 2016;9. https://doi.org/10.1186/s13045-016-0279-9.
3. Faundes V et al. Histone lysine methylases and demethylases in the landscape of human developmental disorders. Am J Hum Genet. 2018;102:175–187. 10.4137/Geg.S31863.
4. Parkel S, Lopez-Atalaya JP, Barco A. Histone H3 lysine methylation and demethylation in the landscape of human developmental disorders. Am J Hematol. 2016;102:175–187. https://doi.org/10.1002/ajh.24785.
5. Johansson C et al. The roles of Jumonji-type oxygenases in human disease. Epigenomics. 2014;6:89–120. https://doi.org/10.2217/epi.13.79.
6. Aasland R, Gibson TJ. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci. 1995;20:56–59.
Klose RJ, Zhang Y. Regulation of histone methylation by demethylimation and Rasmussen PB, Staller P. The KDM5 family of histone demethylases as targets in Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bossé R, Bielefeld M. Curr Chem Genomics. 2008;1:2–10.

7. Sanchez R, Zhou MM. The PHD finger: a versatile epigenome reader. Trends Biochem Sci. 2011;36:364–372. https://doi.org/10.1016/j.tibs.2011.03.005.
8. Zeng L et al. Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPFP3. Nature. 2010;466:258–262. https://doi.org/10.1038/nature09139.
9. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimation and demethylation. Nat Rev Mol Cell Biol. 2007;9:307–318.
10. Christensen J et al. RBP2 belongs to a family of demethylases, specific for tri- and dimethylated lysine 4 on histone 3. Cell. 2007;128:1063–1076. https://doi.org/10.1016/j.cell.2007.02.003.
11. Højfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discovery. 2013;12:917–930. https://doi.org/10.1038/nrd4154.
12. Klose RJ et al. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell. 2007;128:889–900. https://doi.org/10.1016/j.cell.2007.02.013.
13. Iwase S et al. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell. 2007;128:1077–1088. https://doi.org/10.1016/j.cell.2007.02.017.
14. Rasmussen PB, Staller P. The KDM5 family of histone demethylases as targets in oncology drug discovery. Epigenomics. 2014;6:277–286.
15. Roesch A et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013;23:811–825. https://doi.org/10.1016/j.ccr.2013.05.003.
16. Roesch A et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583–594. https://doi.org/10.1016/j.cell.2010.04.020.
17. Klein BJ et al. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers. Cell Rep. 2014;6:325–335. https://doi.org/10.1016/j.celrep.2014.12.021.
18. Torres IO et al. Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism. Nat Commun. 2015;6:6204. https://doi.org/10.1038/ncomms7204.
19. van Zutven LJ et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12q13) as a new partner gene. Genes Chromosomes Cancer. 2006;45:437–446. https://doi.org/10.1002/gcc.20308.
20. Wang GG et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2005;439:847–851. https://doi.org/10.1038/nature04036.
21. Cao J et al. Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep. 2014;6:868–877. https://doi.org/10.1016/j.celrep.2014.02.004.
22. McAlister TE et al. Recent Progress in Histone Demethylase Inhibitors. J Med Chem. 2016;59:1308–1329. https://doi.org/10.1021/acs.jmedchem.5b01759.
23. Kaniskan HU, Jin J. Recent progress in developing selective inhibitors of protein methyltransferases. Curr Opin Chem Biol. 2017;39:100–108. https://doi.org/10.1016/j.cbpa.2017.06.013.
24. Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630–641. https://doi.org/10.1038/nrg.2016.53.
25. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discovery. 2012;11:384–400. https://doi.org/10.1038/nrd3674.
26. Wagner EK, Nath N, Fleming R, Feltgenberger JR, Denu JM. Identification and characterization of small molecule inhibitors of a plant homeodomain finger. Biochemistry. 2012;51:8293–8306. https://doi.org/10.1021/bi3009278.
27. Miller TC et al. Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger. ACS Chem Biol. 2014;9:2864–2874. https://doi.org/10.1021/cb500558s.
28. PerkinElmer. Sensitive homogeneous assay technology, <http://www.perkinelmer.com/Content/RelatedMaterials/Brochures/BRO_AlphaScreen2004.pdf> (2004).
29. Tumber A et al. Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells. Cell Chem Biol. 2017;24:371–380. https://doi.org/10.1016/j.chembiol.2017.02.006.
30. Horton JR et al. Enzymatic and structural insights for substrate specificity of a family of jumonji histone lysine demethylases. Nat Struct Mol Biol. 2010;17:38–43. https://doi.org/10.1038/nsmb.1753.
31. Fortschegger K, Shiekhattar R. Plant homeodomain fingers form a helping hand for transcription. Epigenetics. 2011;6:4–8. https://doi.org/10.4161/epi.6.1.17297.
32. Gul S. Epigenetic assays for chemical biology and drug discovery. Clin Epigenet. 2017;9. https://doi.org/10.1186/s13040-017-0047-5.
33. Kwak AHY, Cell DA, Verger A, Crossley M, Matthews JM, Mackay JP. Engineering a Protein Scaffold from a PHD Finger. Structure. 2003;11(7):803–813. https://doi.org/10.1016/j.str.2003.07.009.
34. Eglen RM, Reisine T, Boly P, Rouleau N, Ily C, Bossé R, Bielefeld M. Curr Chem Genomics. 2008;1:2–10.